Navigation Links
PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers
Date:9/22/2010

Food and Drug Administration (FDA) to discuss biosimilar product development programs.  According to Dr. Babbitt, a well-defined regulatory pathway for biosimilars has been operating in Europe since 2005, and the U.S. is now poised to enter this marketplace.  As noted in the white paper, the FDA is planning to spend $5.7 million in Fiscal 2011 to develop drug review standards specific for biosimilars.  In addition, key aspects of the legislation are discussed as well as how biosimilarity and potentially interchangeability to innovator products is to be demonstrated.

"How Can the Biosimilar Concept Be Applied to More Complex Proteins Such as Monoclonals?" further examines the potential development of biosimilar versions of approved mAbs. The white paper addresses the robustness of the mAb market, which is anticipated to increase at a compound annual growth rate of nearly 11 percent, and discusses approval pathways for biosimilar mAbs that could propel the biosimilars market. The white paper reviews the complex structure of mAbs, the value of nonclinical data, new thinking required in early development and the challenges of confirmatory efficacy trials.

"Demonstrating therapeutic equivalence for monoclonals will be challenging and companies will need to consider their options carefully," said Mr. Nick. "The biosimilar industry along with regulators will need to apply state of the art methodologies and novel approaches for biosimilar monoclonals to become a reality."

The white papers, part of PAREXEL Consulting's Intelligent Development Series, which provides data and insights in support of successful biopharmaceutical and medical device product development, are available at: http://www.PAREXEL.com/services-and-capabilities/consulting/our-thinking/whitepapers.

About PAREXEL International PAREXEL International Corpor
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
2. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
3. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
4. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
5. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
8. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
9. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
10. PAREXEL Expands Global Clinical Pharmacology Capabilities
11. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- The U.S. Department of Health and Human Services (HHS) ... Case Medical Center Seidman Cancer Center totaling $4.7 million ... care for patients with complex cancer. ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... levels following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus ... tolerability comparable to ... - Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., ... of a 4-week Phase 1,clinical trial to evaluate two oral dose levels ...
... Duration of ... Neutropenia- ... Jan. 7 Maxygen, Inc.,(Nasdaq: MAXY ) today announced positive progress in ... the trial include the following:, -- Patients in the initial 10 ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 2Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 4
(Date:7/11/2014)... July 11, 2014 As reported by ... For Cocaine: Are Genetics To Blame (6/30), Indino Downey ... cocaine and paraphernalia to smoke it with. His father, ... that his son inherited from him may have something ... made the news during the 1980s and 1990s for ...
(Date:7/11/2014)... July 11, 2014 Organic Crop ... being launched into the limelight over the past decade. ... was once considered to be an alternative food eaten ... are now purchasing organic food.” Organic crop farmers have ... vegetables, grains, nuts and herbs over the past five ...
(Date:7/11/2014)... new study challenges the widely held belief that light drinking ... analyzed more than 50 studies that examined drinking habits and ... that those with a form of a gene tied to ... affects how a person,s body breaks down alcohol, resulting in ... variant has been shown to lead to lower drinking over ...
(Date:7/11/2014)... 2014 American Farmer is proud to ... July 15, 2014, at 8:30 am ET. , In ... products, which are designed and formulated for use on ... how these products help the crop realize its maximum ... is grown. , The show also features UniSouth Genetics, ...
(Date:7/11/2014)... WA (PRWEB) July 11, 2014 College ... within one week of injury, but developed recurrent instability ... at the American Orthopaedic Society for Sports Medicine’s ( ... guide team physicians in providing the most optimal treatment ... who suffered an anterior shoulder instability event, and found ...
Breaking Medicine News(10 mins):Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:A Little Alcohol May Not Be Good for Your Heart After All 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Intercollegiate Contact Athletes with Shoulder Instability Return to In-Season Sports, Study Shows 2
... support efforts to reduce air pollution, especially diesel exhaust ... studies from Europe demonstrate the health damage done by ... engines. , An 11-year period of improving air quality ... air in Europe, produced measurable benefits in lung function ...
... healthy lifestyle drives new store openings, PITTSBURGH, Dec. ... new resolution or two. For GNC, it means more ... is expected to rise steadily,through 2012, according to the ... to once again expand its store base and overall,business: ...
... Ky., Dec. 5 Ventas, Inc. (NYSE:,VTR) ... the Executive,Compensation Committee of its Board of ... certain executive officers to encourage their,long-term retention ... to,Raymond J. Lewis, the Company,s Chief Investment ...
... Growing price competition from,low-cost manufacturers has been forcing ... profitable growth, which Kalorama Information predicts,will likely come ... pharmaceutical,medical foods, or biomedical device companies -- a ... Healthcare Opportunities for Food Ingredient,Manufacturers., Thousands of ...
... still debated, experts say , , WEDNESDAY, Dec. 5 (HealthDay News) ... Wednesday that the cancer drug Avastin should not be used ... close vote, 5-4, the advisers decided the drug,s ability to ... increased risk of blood clots and other cardiovascular troubles among ...
... A new white paper,published by The Endocrine ... major new initiatives to ensure effective,broad-based minority participation ... of recommendations to ensure that data from clinical,trials ... The white paper, developed by a special ...
Cached Medicine News:Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 4Health News:Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 3Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 2Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 3Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 4
... Plate is a semi-rigid system intended ... The Slim-LOC is based on the ... current market technology. The Slim-LOCTM system ... instrumentation. Reduced width (16 mm), low ...
... SC-Acufix anterior cervical plate system is a ... integrated swivel, which provides for consistent, reliable ... bone screw disengagement or backout. This innovative ... locking screw. Simply implant your screws and ...
... a leading provider of telemedicine solutions. ... state-of-the-art technology deliver accurate, reliable and ... professionals and clients in improving outcomes. ... ECG technology to gather patient data, ...
... is a high performance temperature controlled shaker ... shaking speed and incubation time are fully ... parameters are displayed on the LCD in ... below the microplates provide uniform incubation with ...
Medicine Products: